FENC Earnings

FENC reported its earnings on 2026-05-14, showcasing a revenue of 15.11M against an estimate of 13.94M, resulting in a 8.38% surprise. The EPS was 0.01, surpassing the expected -0.02 by 150%. The stock experienced a 36.48% price change on the earnings day and a 44.17% change over the next five days, reflecting market reactions to the results.

Following FENC's earnings announcement on 2026-05-14, the stock price moved by 36.48% on the day of the release. Over the subsequent five days, it saw a 44.17% change. Historically, FENC's stock price tends to shift by an average of 1.7% in the 10 days leading up to earnings and 5.73% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate FENC's annual revenue to reach 19.38M, while the EPS is projected at 0.19. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between FENC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FENC's stock price typically moves by 1.7% in the 10 days before its earnings and 5.73% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.19 and revenue of 19.38M.

The earnings call reveals strong financial performance, with a 73% increase in net product sales and positive cash flow. The strategic global expansion and clinical initiatives, coupled with market exclusivity until 2033, further strengthen the outlook. Despite minor concerns about milestone payment uncertainties and operational ramp-up, the positive sentiment is bolstered by optimistic guidance, robust shareholder return plans, and the potential for label expansion through ISTs. The Q&A session supports this sentiment, highlighting growth in demand and strategic targeting of high-volume prescribers.